The question
NAD Boosters and Human Function
This is the specific idea being tested.
The Hypothesis Critic · A guide for everyone
NAD Boosters and Human Function
NAD Boosters and Human Function
What you need to knowNMN raises blood NAD; older-adult gait signals are tentative and inconsistent, with no established broader physical or longevity benefit.Relative explanatory fit: Alternative ranked ahead
Why the alternative fits better: Controlled NAD rise coexists with stepping, strength, aerobic and disease-specific nulls; direct gait positives remain bounded. Dissociation does not demonstrate which pathway causes every genuine positive or that all supplementation is ineffective.
Review summary
Claim assessed: Nicotinamide mononucleotide supplementation improves physical function in older adults.
Finding: Primary SC2 tentatively crosses Δ, with Low confidence, because the registered physical-function gate includes a genuine assigned secondary gait contrast. The quality concerns—multiple endpoints, incomplete twelve-week observations, an older trial allocation error and exploratory testing—are not hidden or converted into an unstated primary-endpoint requirement. Functional benefit is inconsistent across measures and contexts, and a separate emerging longer-dose trial adds a null boundary. Evidence does not establish broad strength/exercise efficacy, isolated NAD necessity or human longevity. SC1/SC3 marker-to-clinical inference and SC4 molecule equivalence remain separately bounded.
Key points
- SC1: NMN supplementation increases NAD-related exposure markers. — HSEF Γ, Low confidence.
- SC2: NMN improves physical function against placebo in older adults. — HSEF Δ, Low confidence.
- SC3: Functional benefit establishes slower aging or longer human lifespan. — HSEF Γ, Low confidence.
- SC4: Nicotinamide riboside and metformin have equivalent healthy-aging benefits. — HSEF Α, Low confidence.
Verdict and review details
- Evidence grade
- HSEF Δ — First field-valid causal perturbation crossed
- Confidence
- Low
- Framework
- HSEF v5.3
- Review date
- Literature cutoff
- Published
- Review attribution (recorded)
- Codex
Evidence scope: 70 primary reports; literature cutoff 2026-10-13; source examination UTC date 2026-10-13; bounded critical review, not exhaustive systematic review.
The grade applies to the stated claim. Model rankings and individual subclaim grades remain separate from the overall causal-evidence grade.
Full scientific assessment and references · Scorecard (JSON) · Review source (Markdown)
The result at a glance
NMN raises blood NAD; older-adult gait signals are tentative and inconsistent, with no established broader physical or longevity benefit.
Best fit in this review
Exposure and functional response are partly dissociated
Controlled NAD rise coexists with stepping, strength, aerobic and disease-specific nulls; direct gait positives remain bounded. Dissociation does not demonstrate which pathway causes every genuine positive or that all supplementation is ineffective.
Evidence for the stated claim
First causal test
A higher rank means a better fit to the evidence in this comparison. It does not prove every part of the leading explanation.
Which explanation fits?
Another explanation fits better.
A separate question from the causal evidence grade
How does this explanation compare with alternatives?
Alternative ranked aheadThe reviewed hypothesis ranks 2 among 4 models compared; 1 alternative model(s) hold first rank for this stated claim.
Claim under review: rank 2 among 4 compared models.
Leading explanation: Exposure and functional response are partly dissociated.
Position in this comparison: Next after leading rank.
The causal grade asks how well the stated causal claim is established. This comparison asks which of the assessed explanations fits the reviewed findings better. A leading explanation can remain unproven. Models can overlap or include the tested mechanism; an alternative ahead does not make that mechanism irrelevant. These ordinal ranks apply within this review; they do not measure the size of a difference or rank scientific strength across topics.
Idea being tested · rank 2
NAD Boosters and Human Function
First causal test for the stated claim.
Best fit in this review · rank 1
Exposure and functional response are partly dissociated
Controlled NAD rise coexists with stepping, strength, aerobic and disease-specific nulls; direct gait positives remain bounded. Dissociation does not demonstrate which pathway causes every genuine positive or that all supplementation is ineffective.
These explanations can overlap. Ranking their fit to the evidence is separate from deciding how firmly a cause has been established.
See all the explanations compared
Rank 1: Exposure and functional response are partly dissociated — NMN raises NAD while clinical effects vary by measure, baseline physiology and trial context.
Rank 2: NMN restores a functionally limiting NAD pathway — NMN exposure can improve selected older-adult performance by restoring a limiting pathway.
Rank 3: Secondary testing and study conduct contribute to apparent benefit — Practice, multiple outcomes, incomplete data and disrupted allocation can generate nominal signals.
Rank 4: Distinct molecules and disease states have distinct effects — NR, NMN and metformin act through overlapping but non-equivalent pathways and patient settings.
What this means
?
First causal test
NMN raises blood NAD; older-adult gait signals are tentative and inconsistent, with no established broader physical or longevity benefit.
Evidence rating: Δ · Low confidence. How the evidence was assessed.
The important distinction
Controlled NAD rise coexists with stepping, strength, aerobic and disease-specific nulls; direct gait positives remain bounded. Dissociation does not demonstrate which pathway causes every genuine positive or that all supplementation is ineffective.
Health and treatment
Primary SC2 tentatively crosses Δ, with Low confidence, because the registered physical-function gate includes a genuine assigned secondary gait contrast. The quality concerns—multiple endpoints, incomplete twelve-week observations, an older trial allocation error and exploratory testing—are not hidden or converted into an unstated primary-endpoint requirement. Functional benefit is inconsistent across measures and contexts, and a separate emerging longer-dose trial adds a null boundary. Evidence does not establish broad strength/exercise efficacy, isolated NAD necessity or human longevity. SC1/SC3 marker-to-clinical inference and SC4 molecule equivalence remain separately bounded.
From an idea to an explanation
Seeing two things together does not prove one causes the other.
What is observed?
Look for the proposed factor and the outcome, in the people or systems covered by the claim.
What else explains it?
Exposure and functional response are partly dissociated. Controlled NAD rise coexists with stepping, strength, aerobic and disease-specific nulls; direct gait positives remain bounded. Dissociation does not demonstrate which pathway causes every genuine positive or that all supplementation is ineffective.
What test tells them apart?
Randomize baseline-defined ≥60 adults to exact NMN formulation and matched placebo for24weeks, with gait/strength/capacity prespecified as primary or multiplicity-controlled co-primary, meaningful effect size and complete assignment-based analysis. Include prospectively defined healthy and impaired-function/diabetes strata with interaction testing, independent blinded assessors and proper allocation auditing. Measure muscle NAD and pathway controls separately, and extend functional/disease follow-up.
What to test next
What evidence would make the answer clearer?
A useful next question
Randomize baseline-defined ≥60 adults to exact NMN formulation and matched placebo for24weeks, with gait/strength/capacity prespecified as primary or multiplicity-controlled co-primary, meaningful effect size and complete assignment-based analysis. Include prospectively defined healthy and impaired-function/diabetes strata with interaction testing, independent blinded assessors and proper allocation auditing. Measure muscle NAD and pathway controls separately, and extend functional/disease follow-up.
Change the proposed cause
Check that the intended change really happened.
Measure the relevant outcome
Allow for other factors and compare with suitable controls.
Check whether it holds up
Look for independent confirmation and the limits of the effect.
These are questions for research, not a claim that the proposed studies have already succeeded.
Read the scientific study designs
Proposed tests: 1 test design(s) are registered in the scorecard.
In plain terms, researchers would change the proposed cause, check that it changed as intended, then measure a meaningful outcome while controlling plausible alternatives. The result should be able to support or count against the claim—not only show that a pathway exists.
Experiment 1: Registered boundary experiment
Study design: Randomize baseline-defined ≥60 adults to exact NMN formulation and matched placebo for24weeks, with gait/strength/capacity prespecified as primary or multiplicity-controlled co-primary, meaningful effect size and complete assignment-based analysis. Include prospectively defined healthy and impaired-function/diabetes strata with interaction testing, independent blinded assessors and proper allocation auditing. Measure muscle NAD and pathway controls separately, and extend functional/disease follow-up.
What would be measured: Prespecified meaningful gait, grip/knee strength and exercise capacity, adverse events and durability; blood/tissue NAD as mechanistic secondary and lifespan/disease trajectory separate.
Important controls: Matched formulations, independent blinded function assessment and allocation audit, practice-effect/run-in measurement, full-population estimands, missing-data sensitivity, prospective multiplicity and baseline-stratum interaction.
Result that would support the claim: A clear replicated functional treatment contrast with adequate precision would strengthen the tentative crossing and map context; mediation needs independently targeted pathway evidence.
Result that would count against it: Exposure increase without multiplicity-controlled function leaves benefit unconfirmed in that context; no posthoc NAD-responder or favorable-test exclusion can rescue the assigned result.
Explore the evidence
Read the complete scientific review.
Follow the studies, detailed comparisons and evidence ratings behind this guide.
Open the scientific review →